5 Conclusion:
Overall, the results presented are encouraging and provide clear
evidence that exploring the subregional mechanisms of mPFC is of great
significance for further understanding the pathogenesis and treatment of
depression. In ICV-STZ rats, IDO is activated either in PrL or in IL,
but the mechanisms involved in the regulation of depressive behaviors of
the two subregions are obviously different. 1-MT, a selective inhibitor
of IDO, can reverse ICV-STZ-induced depressive behavior by ameliorating
astrocyte defects in the PrL or inhibiting IL microglial
hyperactivation. These findings provide valuable information for further
understanding the pathogenesis of depression and discovering a novel
target for depression treatment.